At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02269 WUXI BIO
Closed 09-01 16:08:13
49.480
+0.640
+1.31%
High50.350Low48.180Vol32.64M
Open48.860D1 Closing48.840Amplitude4.44%
Mkt Cap205.09BTradable Cap205.09BTotal Shares4.15B
T/O1.61BT/O Rate0.79%Tradable Shares4.15B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Wuxi Biologics (Cayman) Stock Slips 3.6% in Hong Kong
Dow Jones  ·  08-31 16:32
Wuxi Biologics (Cayman) Stock Slips 3.6% in Hong Kong
WuXi Biologics' Stronger Project Backlog Could Underpin Revenue Visibility
Dow Jones  ·  08-31 16:13
WuXi Biologics' Stronger Project Backlog Could Underpin Revenue Visibility
Movement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results
Market Focus  ·  08-31 09:40
Movement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results
WuXi XDC Files HKEX Next-Day Disclosure Return, Lifts Share Capital by 1,707,842 Shares
Reuters  ·  08-28
WuXi XDC Files HKEX Next-Day Disclosure Return, Lifts Share Capital by 1,707,842 Shares
China's Joinn Laboratories H1 Profit Jumps 1,127% on Strong Drug Demand
Reuters  ·  08-28
China's Joinn Laboratories H1 Profit Jumps 1,127% on Strong Drug Demand
Hong Kong's Frontage Holdings H1 Profit More than Doubles on Teddy Lab Acquisition
Reuters  ·  08-28
Hong Kong's Frontage Holdings H1 Profit More than Doubles on Teddy Lab Acquisition
CMB International Lifts WUXI BIO Price Target to HK$60, Maintains "Buy" Rating
Stock News  ·  08-28
CMB International Lifts WUXI BIO Price Target to HK$60, Maintains "Buy" Rating
Biocytogen Pharmaceuticals H1 Revenue up 51.6%
Reuters  ·  08-27
Biocytogen Pharmaceuticals H1 Revenue up 51.6%
Movement Alert｜WUXI BIO Declines 3.05% in Regular Trading, Profit-Taking After Strong Mid-Year Results Triggers CXO Sector Pullback
Market Focus  ·  08-27
Movement Alert｜WUXI BIO Declines 3.05% in Regular Trading, Profit-Taking After Strong Mid-Year Results Triggers CXO Sector Pullback
VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds
Reuters  ·  08-26
VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds
HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%
Tiger Newspress  ·  08-26
HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%
Movement Alert｜WUXI BIO Rises 4.02% in Regular Trading, Strong Interim Results and Raised Full-Year Guidance Fuel Rally
Market Focus  ·  08-26
Movement Alert｜WUXI BIO Rises 4.02% in Regular Trading, Strong Interim Results and Raised Full-Year Guidance Fuel Rally
WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?
Simply Wall St.  ·  08-26
WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?
WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme
Reuters  ·  08-25
WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme
WuXi Biologics Reports Strong Profitable Growth in H1 2026
THOMSON REUTERS  ·  08-25
WuXi Biologics Reports Strong Profitable Growth in H1 2026
WuXi Biologics H1 Net Profit up on Margin Expansion
Reuters  ·  08-25
WuXi Biologics H1 Net Profit up on Margin Expansion
Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis
Stock News  ·  08-25
Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis
WuXi Bio Posts Robust H1 2026: Revenue Hits RMB 11.79 Billion, Adjusted Gross Margin Widens to 48.4%; Raises FY Growth Guidance
Bulletin Express  ·  08-25
WuXi Bio Posts Robust H1 2026: Revenue Hits RMB 11.79 Billion, Adjusted Gross Margin Widens to 48.4%; Raises FY Growth Guidance
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Stock News  ·  08-25
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
WuXi Biologics Posts Higher Adjusted Attributable Profit in H1
MT Newswires Live  ·  08-25
WuXi Biologics Posts Higher Adjusted Attributable Profit in H1
No data available

Introduction

Company Name.
WUXI BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
Issue price:
--